MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 04-25-2026
Autolus Therapeutics plc Total Liabilities 2011-2026 | AUTL
Annual Total Liabilities Autolus Therapeutics plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 411 M | 355 M | 264 M | 192 M | 92.2 M | 84.2 M | 48.7 M | 21.6 M | 6.06 M | 3.49 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 411 M | 3.49 M | 148 M |
Quarterly Total Liabilities Autolus Therapeutics plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 396 M | 375 M | 375 M | 351 M | 326 M | 319 M | 226 M | - | - | - | - | - | - | 92.2 M | - | - | 50.2 M | 84.2 M | 80.3 M | 51.6 M | 50.2 M | 48.7 M | 45 M | 47.9 M | - | 21.6 M | 17.7 M | - | - | - | 6.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 396 M | 6.06 M | 156 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B |  USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
7.43 M | - | -19.68 % | $ 18.4 M |  Canada |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
4.9 M | $ 0.9 | -2.33 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 21.96 | -0.68 % | $ 3.64 B | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
22.7 M | $ 1.02 | -0.49 % | $ 428 M |  Israel |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Aligos Therapeutics
ALGS
|
35 M | $ 6.4 | 4.4 % | $ 63.3 M | USA |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 21.41 | 1.9 % | $ 1 B | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
16.3 M | $ 12.26 | 3.72 % | $ 1.62 B |  Australia |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 105.46 | -0.09 % | $ 27.2 B | Germany |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.08 | 0.25 % | $ 436 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 23.26 | 1.75 % | $ 2.96 B | USA |
 |
Cara Therapeutics
CARA
|
11.1 M | - | -3.03 % | $ 260 M | USA |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BioXcel Therapeutics
BTAI
|
140 M | $ 1.06 | -3.64 % | $ 12.9 M | USA |
 |
CASI Pharmaceuticals
CASI
|
30.3 M | - | - | $ 35.4 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Cabaletta Bio
CABA
|
53 M | $ 2.95 | -3.28 % | $ 296 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 2.91 | -1.36 % | $ 4.79 M | Israel |
 |
bluebird bio
BLUE
|
425 M | - | - | $ 546 M | USA |
 |
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |